ScreenPoint Medical Showcases Transpara® Powered by FusionAI at RSNA

ScreenPoint Medical is showcasing its world leading breast care system Transpara powered by Fusion AI at the annual RSNA Annual Meeting in Chicago.

It follows a year of major achievements for the organisation with Transpara which is now installed in health care facilities both across the US and in over 25 countries worldwide.

The success of FDA cleared Transpara AI has been marked by a record number of peer-reviewed papers and well over 2,000,000 mammograms being read by this unique system.

Transpara’s developers, ScreenPoint Medical is expanding its operations in the US to meet customer demand and its success has meant the company has also attracted a $28 million capital injection from Insight Partners and URG to help it expand.

Among other milestones in this remarkable year:

  • Forming a new supervisory board whose members include internationally recognized breast radiologist Dr Rachel Brem and Allyson White, Principal at Insight Partners.
  • A record number of new peer-reviewed papers plus five more studies being presented at RSNA.
  • A new trial of Transpara was used in a Danish government screening role to underline use in times of shortage of radiologists.
  • A major new partnership signed with Aidoc, the leading provider of AI for medical imaging, which will incorporate Transpara’s capabilities into Aidoc’s platform.

ScreenPoint Medical’s, VP of US Sales, Nicki Bryan, said 2021 has been the year when using AI to find breast cancers faster and earlier has been universally accepted as a vital tool in the battle to improve survival rates.

“We have proven that AI is a vital tool for early detection of breast cancer, particularly at a time when screening backlogs have grown because of Covid and when there is a worldwide shortage of breast radiologists. Transpara’s powerful benefits are being used daily around the world, helping radiologists to provide the world class care every woman deserves.”

Hot this week

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution